Clinical trials: Urinary
Overactive Bladder, Urinary Urge Incontinence
InterStim Basic Evaluation Lead Post-Market Clinical Follow-up Study
Post-market clinical follow-up for continued assessment of safety and performance of the InterStim basic evaluation lead and foramen needle(s) used during a therapy evaluation.
- Conditions
- Overactive Bladder, Urinary Urge Incontinence, Urgency-frequency Syndrome
- Trial name
- BASIC (NCT04016324)
- Testing
- InterStim Basic Evaluation lead and foramen needle
- Where
- 15 sites in United States, Canada and 2 more
- Volunteers
- 110 people
- Sponsor
- MedtronicNeuro
Urinary Bladder Cancer, Muscle-invasive
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
This is a study of perioperative pembrolizumab or enfortumab vedotin in combination with pembrolizumab in participants who are cisplatin-ineligible or decline cisplatin with muscle-invasive bladder cancer (MIBC).
- Trial name
- NCT03924895
- Testing
- Pembrolizumab, Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]), Enfortumab Vedotin
- Where
- 242 sites in United States, Argentina and 26 more
- Volunteers
- 595 people
- Sponsor
- Merck Sharp & Dohme LLC
Bladder Cancer Cell Transitional, Non-Muscle Invasive Bladder Cancer
Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
This is a single-arm, phase 1/2a study of formulated paclitaxel in subjects with low-grade, noninvasive papillary carcinoma (stage Ta) of the bladder.
- Conditions
- Bladder Cancer Cell Transitional, Non-Muscle Invasive Bladder Cancer, Bladder Cancer, Urinary Bladder
- Trial name
- NCT03081858
- Testing
- TSD-001
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- Lipac Oncology LLC
Lupus Nephritis
AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)
To assess the efficacy of 2 doses of voclosporin compared to placebo in achieving complete remission after 24 weeks of therapy in subjects with active lupus nephritis.
- Trial name
- AURA-LV (NCT02141672)
- Testing
- Voclosporin High Dose, Voclosporin Low Dose
- Where
- 86 sites in United States, Bangladesh and 18 more
- Volunteers
- 265 people
- Sponsor
- Aurinia Pharmaceuticals Inc.
Urinary Bladder Neoplasms
Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma
The primary objectives of this study are (Phase 1) to determine in subjects with unresectable or metastatic bladder cancer who have never had chemotherapy, the dose of lenalidomide that is well-tolerated when given in combination…
- Trial name
- NCT01342172
- Testing
- Lenalidomide
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Renal Cell Cancer, Melanoma
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and expansion study intended to evaluate the safety, viral load kinetics and shedding, pharmacodynamic, and anti-tumor activity of…
- Conditions
- Renal Cell Cancer, Melanoma, Non-Small-Cell Lung Cancer, Hepatocellular Cancer
- Trial name
- NCT05061537
- Testing
- PF-07263689, Sasanlimab
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- Pfizer
Kidney Stones
Trial Comparing Three Different Devices for Kidney Stone Removal During Percutaneous Surgery
The investigators plan to compare three different devices that are used to break up large kidney stones during surgery for removal to see if one is faster or more efficient than the others.
- Trial name
- NCT00952315
- Testing
- Cyberwand, Stonebreaker, Lithoclast Select
- Where
- 10 sites in United States, Canada
- Volunteers
- 270 people
- Sponsor
- Indiana Kidney Stone Institute
Urinary Tract Infections
Fecal Microbiota Transplantation (FMT) for MDRO UTI
The purpose of this study is to determine the safety and impact of fecal microbiota transplantation (FMT) on the fecal and urine microbiome, urine metabolome, risk of recurrent urinary tract infection (UTI), and persistent…
- Trial name
- NCT03367910
- Testing
- Fecal microbiota transplant
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Washington University School of Medicine
Interstitial Cystitis, Chronic Interstitial Cystitis
PEMF Therapy to Treat Interstitial Cystitis/Bladder Pain Syndrome
The purpose of this study is to gather information from the investigation of a non-pharmacological (non-drug) treatment known as low frequency pulsed electromagnetic field (PEMF).
- Conditions
- Interstitial Cystitis, Chronic Interstitial Cystitis, Bladder Pain Syndrome
- Trial name
- NCT04540887
- Testing
- Pulsed Electromagnetic Field (PEMF) Therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Wake Forest University Health Sciences
Urinary Tract Infections, Catheter Infection
Reducing Urinary Tract Infection Rates Using a Controlled Aseptic Protocol for Catheter Insertion
Urinary Tract Infection (UTI) complications following catheter use in surgical patients remains high. Using an aseptic protocol has been shown to drastically reduce UTI incidence by 50%.
- Conditions
- Urinary Tract Infections, Catheter Infection, Catheter-Related Infections
- Trial name
- NCT03101371
- Testing
- Catheter insertion with Povidone Iodine, Standard of care catheter insertion
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- University of Colorado, Denver
Overactive Bladder
PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB
To evaluate the NURO system for the treatment of OAB in drug naïve patients.
- Trial name
- RESET (NCT02857816)
- Testing
- NURO System PTNM Therapy
- Where
- 11 sites in United States
- Volunteers
- 154 people
- Sponsor
- MedtronicNeuro
Bladder Pain Syndrome
The Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Female Participants With Interstitial Cystitis /Bladder Pain Syndrome (MK-7264-005)
The purpose of this study is to assess the efficacy of gefapixant (AF-219/MK-7264) in female participants with moderate to severe pain associated with interstitial cystitis/bladder pain syndrome (IC/BPS) after 4 weeks of…
- Trial name
- NCT01569438
- Testing
- Gefapixant
- Where
- 41 sites in United States
- Volunteers
- 107 people
- Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Parastomal Hernia
Prevention of Parastomal Hernia by Mesh Placement
Concurrent placement of a mesh during formation of ileal conduit will decrease the incidence of parastomal hernia and associated complications.
- Trial name
- NCT02404545
- Testing
- Ethicon Physiomesh
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Miami
Urinary Incontinence, Urinary Bladder
OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)
This was a multicenter, randomized, double-blind, parallel-group, multiple-dose study to evaluate the efficacy and safety of BOTOX in adolescents with urinary incontinence due to overactive bladder (OAB) with inadequate…
- Conditions
- Urinary Incontinence, Urinary Bladder, Overactive
- Trial name
- NCT02097121
- Testing
- BOTOX®
- Where
- 39 sites in United States, Australia and 11 more
- Volunteers
- 56 people
- Sponsor
- Allergan
Melanoma, Solid Tumor
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
This is a Phase 2, multi-center, open-label to evaluate the efficacy and safety of tovorafenib (DAY101) in participants ≥12 years of age with recurrent or progressive melanoma or solid tumors with BRAF fusion or CRAF/RAF1 fusions…
- Conditions
- Melanoma, Solid Tumor, CRAF Gene Amplification, RAF1 Gene Amplification
- Trial name
- NCT04985604
- Testing
- Tovorafenib
- Where
- 20 sites in United States, Australia and 5 more
- Volunteers
- 23 people
- Sponsor
- Day One Biopharmaceuticals, Inc.
Urinary Incontinence
Study to Determine Effects of Vesicare on Return to Continence Post - Radical Prostatectomy (Part II)
Prostate cancer is the most common non-cutaneous malignancy in men and is the 2nd leading cause of death from cancer in men. Radical prostatectomy is one of the treatment options available for organ-confined disease.
- Trial name
- NCT01215721
- Testing
- Vesicare
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of California, Irvine
Lower Urinary Tract Symptoms, Bladder Outlet Obstruction
Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction
A study to evaluate the safety of the co-administration of solifenacin succinate with tamsulosin hydrochloride in men with lower urinary tract symptoms (LUTS) and bladder outlet obstruction (BOO).
- Trial name
- NCT00507455
- Testing
- solifenacin succinate, tamsulosin hydrochloride
- Where
- 33 sites in United States, Belgium and 4 more
- Volunteers
- 222 people
- Sponsor
- Astellas Pharma Inc
Overactive Bladder
Behavioral Treatment of Overactive Bladder in Men
The primary purpose of this project is to evaluate the effectiveness of behavioral treatment compared to standard drug therapy for symptoms of OAB in male veterans.
- Trial name
- MOTIVE (NCT01187498)
- Testing
- Behavioral training, Oxybutynin chloride, extended-release
- Where
- 2 sites in United States
- Volunteers
- 143 people
- Sponsor
- US Department of Veterans Affairs
Postoperative Urinary Retention
The POUR (Postoperative Urinary Retention) Study
The primary aim of this study will be to compare the rate of postoperative urinary retention between patients receiving Sugammadex and those receiving traditional reversal agents
- Trial name
- POUR (NCT05276804)
- Testing
- Sugammadex
- Where
- United States
- Volunteers
- 171 people
- Sponsor
- Wake Forest University Health Sciences
Overactive Bladder
Detrol Long Acting (LA) vs Estrace Vaginal Cream for the Treatment of Overactive Bladder Symptoms
The purpose of this study is to determine if long acting tolterodine confers more benefit than intravaginal low dose estrogen in the treatment of Overactive Bladder Syndrome at 12 weeks post-treatment initiation.
- Trial name
- DRIVE (NCT00465894)
- Testing
- Extended Release Tolterodine LA, Intra Vaginal Estradiol Cream
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.